Apotex – Recall of brimonidine tartrate ophthalmic solution

- On March 1, 2023, Apotex Corp. announced a consumer-level recall of six lots of brimonidine tartrate ophthalmic solution 0.15% due to cracks that have developed in some of the units caps of bottles that may impact sterility and if so, the possibility of adverse events.
    - Other brimonidine tartrate ophthalmic solution products made by other manufacturers that are not being recalled are available for use.
- These lots were distributed nationwide between April 05, 2022 to February 22, 2023.

Product Description	NDC#	Lot# (Expiration Date)
Brimonidine tartrate ophthalmic solution 0.15%, 5 mL	60505-0564-1	TJ9848 (2/2024) TJ9849 (2/2024) TK0258 (4/2024) TK5341 (4/2024)
Brimonidine tartrate ophthalmic solution 0.15%, 10 mL	60505-0564-2	TK0261 (4/2024)
Brimonidine tartrate ophthalmic solution 0.15%, 15 mL	60505-0564-3	TK0262 (4/2024)

- Brimonidine tartrate ophthalmic solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Patients who are currently using the recalled brimonidine tartrate ophthalmic solution should stop use and contact their pharmacy for a replacement. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled product.
- Anyone with an existing inventory of the recalled product should stop use, distribution, and quarantine the product immediately and arrange for return.
- Contact Apotex Corp. by phone at **1-800-706-5575** or by e-mail at **UScustomerservice@Apotex.com** for questions regarding this recall.